CDSCO panel noted Biological E's Post Marketing Surveillance Report of Monovalent recombinant Hepatitis-B vaccine
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has noted the post-marketing surveillance report of the Monovalent recombinant Hepatitis-B vaccine study titled “A multicentre single arm, post marketing surveillance study to evaluate the safety of Biological E’s Monovalent recombinant Hepatitis-B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedules”.
This came after the vaccine major Biological E presented the post-marketing surveillance report of the Monovalent recombinant Hepatitis-B vaccine study titled “A multicentre single arm, post-marketing surveillance study to evaluate the safety of Biological E’s Monovalent recombinant Hepatitis-B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedules”.
Hepatitis B Vaccine (Recombinant) is composed of highly purified hepatitis B surface antigen (HBsAg) adsorbed to an aluminum adjuvant. The antigen is produced from the fermentation of a recombinant strain of yeast, Saccharomyces cerevisiae.
At the recent SEC meeting for Vaccine 30th April 2024, the expert panel reviewed the post-marketing surveillance report of Monovalent recombinant Hepatitis-B vaccine study titled “A multicentre single arm, post marketing surveillance study to evaluate the safety of Biological E’s Monovalent recombinant Hepatitis-B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedules" presented by the drug major Biological E.
After detailed deliberation, the committee noted the results of the PMS study as presented by the firm.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.